Abstract
BackgroundThe best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have